186 related articles for article (PubMed ID: 30583488)
1. In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors.
Fage C; Abed Y; Checkmahomed L; Venable MC; Boivin G
Viruses; 2018 Dec; 11(1):. PubMed ID: 30583488
[TBL] [Abstract][Full Text] [Related]
2. Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.
Burnham AJ; Armstrong J; Lowen AC; Webster RG; Govorkova EA
J Virol; 2015 Apr; 89(8):4575-87. PubMed ID: 25673705
[TBL] [Abstract][Full Text] [Related]
3. Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses.
Tu V; Abed Y; Fage C; Baz M; Boivin G
Antiviral Res; 2018 Jun; 154():110-115. PubMed ID: 29674164
[TBL] [Abstract][Full Text] [Related]
4.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
5. Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
Pascua PNQ; Marathe BM; Bisen S; Webby RJ; Govorkova EA
Antiviral Res; 2020 Jan; 173():104669. PubMed ID: 31790712
[TBL] [Abstract][Full Text] [Related]
6. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
[TBL] [Abstract][Full Text] [Related]
7. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.
Burnham AJ; Baranovich T; Marathe BM; Armstrong J; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2014 May; 58(5):2718-30. PubMed ID: 24566185
[TBL] [Abstract][Full Text] [Related]
8. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
[TBL] [Abstract][Full Text] [Related]
9. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
[TBL] [Abstract][Full Text] [Related]
10. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
[TBL] [Abstract][Full Text] [Related]
11. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
12. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
[TBL] [Abstract][Full Text] [Related]
13. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
[TBL] [Abstract][Full Text] [Related]
14.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.
Farrukee R; Zarebski AE; McCaw JM; Bloom JD; Reading PC; Hurt AC
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201817
[TBL] [Abstract][Full Text] [Related]
16. Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets.
Pascua PN; Marathe BM; Burnham AJ; Vogel P; Webby RJ; Webster RG; Govorkova EA
PLoS One; 2016; 11(7):e0159847. PubMed ID: 27466813
[TBL] [Abstract][Full Text] [Related]
17. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
Tang J; Gao R; Liu L; Zhang S; Liu J; Li X; Fang Q; Feng Z; Xu C; Huang W; Wang D
Sci Rep; 2021 Aug; 11(1):16293. PubMed ID: 34381119
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
PLoS One; 2018; 13(1):e0190877. PubMed ID: 29324781
[TBL] [Abstract][Full Text] [Related]
19. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Farrukee R; Butler J; Reading PC; Hurt AC
Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
[TBL] [Abstract][Full Text] [Related]
20. Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Bialy D; Shelton H
Antiviral Res; 2020 Oct; 182():104886. PubMed ID: 32750468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
